Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of COPD and post-bronchodilator FEV1 ≥ 50% of the predicted normal value and post-bronchodilator FEV1/FVC \< 0.7 (COPD Grade 1 or 2 by severity of airflow limitation (GOLD 2015)~* Patients with CAT score ≥ 10 at Visit 0 and Visit 1.~* Patients who are on and have been on tiotropium monotherapy for the past 3 months.~* 0 or 1 COPD exacerbation in the previous 12 months (not leading to hospital admission).~Exclusion Criteria:~* Treatment with any inhaled corticosteroid (ICS) in the 3 months prior to Visit 1.~* COPD exacerbation between Visit 0 and 1.~* Patients with concomitant pulmonary disease~* Patients with a history of respiratory infection within 4 weeks prior to Visit 0.~* Prior or current diagnosis of asthma.~* Presence of any contraindication, warning, precaution, hypersensitivity to LABA and LAMA~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol and glycopyrronium (QVA149) (Type: EXPERIMENTAL): QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 12 weeks
- Tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).